Date: 2016-07-05
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Boston Biomedical (USA - MA)
Product: napabucasin (BBI608)
Action
mechanism: cancer cell stemness inhibitor. Napabucasin is an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3. Napabucasin is currently being investigated in three Phase III studies in advanced gastric and GEJ , colorectal ) and lung cancer. It is also being investigated in earlier phases in multiple solid and hematologic malignancies, including tumors of the liver, pancreas and brain.
Disease: non squamous non cell lung cancer
Therapeutic area: Cancer - Oncology
Country:
Trial
details: This is an international, multi-center, prospective, randomized, open-label Phase 3 clinical trial of the cancer stemness inhibitor napabucasin administered with weekly paclitaxel versus weekly paclitaxel alone in patients with advanced non-squamous non-small cell lung cancer who have disease progression following systemic treatment with a platinum-based combination regimen in the metastatic setting, who have received treatment with an immune checkpoint inhibitor if a candidate, additional approved therapies, and for whom weekly paclitaxel is an acceptable treatment option. (NCT02826161)
Latest
news: * On July 5, 2016, a Phase 3 trial sponsored by Boston Biomedical was published on the NIH website ClinicalTrials.gov for napabucasin (BBI608) and is currently recruiting participants.
